Analysis of Urogen Pharma (URGN) and VBI Vaccines (VBIV)

VBI Vaccines (NASDAQ: VBIV) and Urogen Pharma (NASDAQ: URGN) are both small-scale medical companies, but which are the superior companies? We will compare the two companies based on the strength of their institutional ownership, recommendations from analysts, dividends, profitability, valuation, risk and income.

Institutional & Insider Ownership

48.0% of VBI Vaccines shares are held by institutional investors. For comparison: 71.1% of the shares of Urogen Pharma are held by institutional investors. 54.5% of the shares of VBI Vaccines are owned by insiders of companies. Strong institutional ownership is an indication that donations, hedge funds and large money managers believe that a share will outperform the market in the long term.

Recommendations from analysts

This is a summary of the current recommendations for VBI Vaccines and Urogen Pharma, as provided by MarketBeat.

Sales reviews Keep ratings Buy ratings Strong sales figures Review score
VBI vaccines 0 0 3 0 3.00
Urogen Pharma 0 0 8 0 3.00

VBI Vaccins currently has a consensus target of $ 11.00, indicating a potential benefit of 354.55%. Urogen Pharma has a target price target of $ 59.60, indicating a potential benefit of 26.19%. Given the higher possible positive effect of VBI Vaccines, analysts clearly believe that VBI vaccines are more favorable than Urogen Pharma.


This table compares VBI vaccines and Urogen Pharma's net margins, return on equity and return on assets.

Net margins Return on equity Return on assets
VBI vaccines -6.175.95% -53.12% -41.20%
Urogen Pharma -470.54% -44.24% -41.48%

Volatility and risk

VBI Vaccines has a beta of 1.43, which indicates that the share price is 43% more volatile than the S & P 500. For comparison: Urogen Pharma has a beta of 1.98, which indicates that the share price is 98% volatile than the S & P 500.

Income and appreciation

This table compares VBI vaccines and the revenue, earnings per share and valuation of Urogen Pharma.

Gross income Price / sales ratio Net income Profit per share Price / profit ratio
VBI vaccines $ 860,000.00 181.16 – $ 38.99 million N / A N / A
Urogen Pharma $ 8.16 million 79.58 – $ 20.00 million ($ 2.14) -22.07

Urogen Pharma has higher income and income than VBI vaccines.


Urogen Pharma beats VBI Vaccines on 7 out of 11 factors compared between the two stocks.

About VBI Vaccines

VBI Vaccines Inc., a biopharmaceutical company, develops and markets vaccines to address unmet needs in infectious diseases and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third generation hepatitis B vaccine for adults, children and newborns; and eVLP, a vaccine platform for designing enveloped virus-like particle vaccines that closely mimic the target virus. It also develops a congenital cytomegalovirus vaccine candidate for infectious diseases; and therapeutic glioblastoma multiforme vaccine candidate for immuno-oncology. The company was formerly known as SciVac Therapeutics Inc. and changed the name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts. VBI Vaccines Inc. is a subsidiary of FDS Pharma ASS.

About Urogen Pharma

UroGen Pharma Ltd., a clinical biopharmaceutical company, focuses on the development of new therapies for urological pathologies. The main product candidates, MitoGel and VesiGel, are proprietary formulations of the chemotherapy drug Mitomycin C, a generic drug that is currently not used for the treatment of urothelial cancer in an aqueous-based formulation as an adjuvant or as a supplement to post-operative therapy. The company develops its product candidates as chemo exposure agents, designed to remove tumors in a non-surgical manner, for the treatment of various forms of non-muscle-invasive urothelial cancer, including low-grade urothelial carcinoma in the upper air ducts and low-level bladder cancer. UroGen Pharma Ltd. was founded in 2004 and is headquartered in Ra & # 39; anana, Israel.

Receive daily news and valuations for VBI vaccines – Enter your e-mail address below to receive a concise, daily summary of the latest news and reviews from analysts for VBI vaccines and related companies with the FREE daily e-mail newsletter from

Source link